The appetite for generic drugs throughout the European Community is expected to double in the next 7 years, jumping from $17.18 billion in 2006 to nearly $36 billion by 2013, according to a new market analysis by Frost & Sullivan. As in the United States, rising health costs in Europe are causing government leaders to explore methods for promoting increased use of more cost-effective generic medicines, the study noted.
?Patent expiries, pro-generic reforms in certain countries, and need for cheap, effective medicines are the key factors driving growth in the European generics market,? a researcher for the company explained. ?Various studies have indicated the cost savings obtained from generics, and several governments in Europe are actively promoting generics.?
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs